Form 4: Niagen Bioscience Director Acquires Stock Options

Ann Cohen, a Director at Niagen Bioscience, Inc., acquired stock options for 31,746 shares of common stock.

Summary

• Ann Cohen, a Director of Niagen Bioscience, Inc. (NAGE), acquired stock options on June 24, 2026.
• The options grant the right to buy 31,746 shares of common stock at an exercise price of $3.45 per share.
• These options are exercisable starting June 24, 2027, and expire on June 23, 2036.
• The transaction was reported on June 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating potential alignment of interests, but does not provide new financial performance data.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price suggests a potential for future value appreciation if the stock price exceeds $3.45.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the options have value only if the stock price rises above the exercise price.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to incentivize management and directors, aligning their interests with shareholders. The specific terms of the options, including the exercise price and vesting schedule, are critical for evaluating their potential impact.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially leading to increased focus on share price appreciation. However, it also represents potential future dilution if options are exercised.
• Management/Directors: The options provide a financial incentive for Ann Cohen to contribute to the company's success and increase shareholder value.

Next Steps

• The director may exercise the stock options if the stock price exceeds the exercise price of $3.45 before the expiration date of June 23, 2036.
• The company's stock performance will determine the ultimate value of these options.

Key Dates

Keywords

Niagen Bioscience, NAGE, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, SEC Filing